Stockreport

Regeneron Is A Phenomenal Growth Story; Buying The Current Dip Could Be A Wise Move [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Summary The phenomenal success of wet AMD and retinopathy treatment Eylea ($7.5 billion sales in 2019) has underpinned Regeneron's strong revenue growth in recent years. [Read more]